Sail Biomedicines Appoints Clinical and Scientific Leader Dr. Wendy Chung to Its Board

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sail Biomedicines, Inc. (“Sail”), a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that Wendy Chung, M.D., Ph.D., has joined Sail’s Board of Directors. Dr. Chung currently serves as Chief of the Department of Pediatrics of Boston Children’s Hospital, sits on the faculty at Harvard Medical School, and is President of the Children’s Hospital Pediatric Associates. She is also the Principal Investigator of GUARDIAN (Genomic Uniform-screening Against Rare Diseases in All Newborns), a study that explores the utility of whole-genome sequencing for screening newborns for rare and treatable genetic conditions.

Dr. Chung brings to Sail’s board more than 20 years of experience as a clinical and molecular geneticist, as well as biotech operational experience. She joined Boston Children’s from Columbia University Irving Medical Center/NewYork-Presbyterian Morgan Stanley Children’s Hospital, where she served as Chief of the Division of Clinical Genetics within the Department of Pediatrics, the Associate Director for Education at the Herbert Irving Comprehensive Cancer Center, the Medical Director for the Columbia Genetic Counseling Graduate Program, and the Precision Medicine Resource Leader at the Irving Institute. Dr. Chung was also the Kennedy Family Professor of Pediatrics in Medicine.

“I’m thrilled to contribute to Sail’s mission to create breakthroughs for patients with new types of RNA therapeutics and to join Sail’s distinguished Board of Directors,” said Dr. Chung. “Sail presents a unique opportunity to unlock programmable RNA medicines for the first time by bringing together first-in-category translatable circular RNA technology, called eRNA, and proprietary programmable nanoparticles, powered by AI. As a clinician as well as a research scientist, I’m truly excited by the potential this may offer patients to access a new category of treatments across a broad range of therapeutic areas, such as oncology, metabolic disease, infectious diseases, rare diseases, and immunology.”

“We are delighted to welcome Dr. Chung to our Board of Directors. She has an extraordinarily accomplished track record and a deep understanding of what we are seeking to achieve from both a clinical and scientific research perspective, which will make her a valuable addition to Sail at this pivotal time for the company, as we speed toward the clinic,” said John Mendlein, Ph.D., Executive Chairman, Sail Biomedicines and Executive Partner, Flagship Pioneering.

About Sail Biomedicines

Sail Biomedicines, a Flagship Pioneering company, is generating tomorrow’s medicines today through the language of life. Sail’s platform combines first-in-category translatable circular RNA technology (Endless RNA™ or eRNA™), and proprietary programmable nanoparticles, utilizing natural components, to comprehensively program medicines for the first time. By leveraging its rapid prototyping and testing bioplatform, Sail is building a wealth of data, enabling unparalleled use of state-of-the-art AI techniques for the integrative design of RNA medicines with unprecedented performance and broad applicability. For more, visit www.sail.bio and follow us on X (formerly Twitter) @SailBiomeds and on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240402833623/en/